Skip to main content
. Author manuscript; available in PMC: 2012 Sep 28.
Published in final edited form as: Nat Rev Rheumatol. 2010 Dec 7;7(4):244–249. doi: 10.1038/nrrheum.2010.193

Table 3.

Clinical trials of gene therapy for osteoarthritis

Transgene Method of delivery Phase Institution or sponsor (principal investigator) Status Number of subjects
TGF-β1 Retrovirus, ex vivo I Kolon Life Sciences, Korea (Ha) Closed 12
TGF-β1 Retrovirus, ex vivo I TissueGene Inc. (Mont)* Closed 12
TGF-β1 Retrovirus, ex vivo IIa Kolon Life Sciences, Korea (Ha) Recruitment Complete 28
TGF-β1 Retrovirus, ex vivo II TissueGene Inc. (Mont)‡ Pending 100
*

NIH Office of Biotechnology Activities protocol number: 0307-594; ClinicalTrials.gov identifier: NCT00599248.

‡

NIH Office of Biotechnology Activities protocol number: 0912-1016.

Abbreviation: TGF-β1, transforming growth factor β1.